摘要
目的探讨阿立哌唑与奥氮平对精神分裂症患者体质量、糖脂代谢的影响。方法将60例精神分裂症患者随机分为两组,分别给予阿立哌唑及奥氮平治疗,于治疗前和治疗后3个月末分别测体质量、空腹血糖及血脂[包括胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白(LDL)及高密度脂蛋白(HDL)]。结果阿立哌唑组治疗前后各项指标差异无显著性(P>0.05),而奥氮平组治疗3个月后体质量、空腹血糖、胆固醇(TC)及甘油三酯(TG)显著升高,差异有显著性(P<0.01或P<0.05)。结论阿立哌唑对体质量、血糖及血脂无明显影响,而奥氮平显著影响体质量,升高了血糖、胆固醇及甘油三酯。
Objective To explore the influence of aripiprazole and olanzapine on body mass, glycolipid metabolism m patients with first-episode schizophrenia. Methods 60 patients with first-episode schizophrenia were randomly divided into two groups treated with aripiprazole and olanzapine respectively for 3 months. Body mass, fasting blood glucose and lipids, which included cholesterol （TC）, triglyceride （TG）, low density lipoprotein （LDL） and high density lipoprotein （HDL） were measured at the baseline and at the end of the treatment. Results At the end of the treatment, all the indexies in aripiprazole group showed no significant changes when compared with the baseline （P 〉 0.05 ）. In olanzapine group, however, the body mass, fasting blood glucose, TC and TG all increased significantly M＇ter 3 months treatment （P 〈 0. 05 ）. Conclusion Aripiprazole has no serious affects on body mass and glycolipid metabolism. But olanzapine can cause weight gain, as well as the increase of blood glucose, cholesterol and triglycerides.
出处
《精神医学杂志》
2011年第5期348-349,共2页
Journal of Psychiatry
关键词
阿立哌唑
奥氮平
体质量
血糖
血脂
精神分裂症
Aripiprazole Olanzapine Body mass Blood glucose Blood lipid Schizophrenia
